7月18日主题复盘 | 稀土再度强势，锂电板块也有表现，创新药持续活跃

Market Overview - The Shanghai Composite Index experienced strong fluctuations throughout the day, reaching a new closing high for the year, while the ChiNext Index saw a pullback after an initial surge [1] - The rare earth permanent magnet sector saw a collective surge, with companies like China Northern Rare Earth and Dongfang Zirconium hitting the daily limit [1][4] - Lithium mining stocks also showed volatility, with Jin Yuan Co. and Shengxin Lithium Energy reaching their daily limits [1] - The innovative drug concept remained active, with Angli Kang hitting the daily limit and Borui Pharmaceutical rising over 10%, both achieving historical highs [1] Key Sectors Rare Earth Materials - The rare earth magnetic materials sector rebounded significantly, with companies such as Dongfang Zirconium and China Northern Rare Earth hitting the daily limit [4] - A new rare earth mineral named "Nd Huanghe Mineral" was discovered in Inner Mongolia, which may impact the supply dynamics in the sector [4] - Analysts believe that the strengthening expectations of supply contraction and the easing of export controls could benefit related rare earth resource companies [5] Lithium Battery - The lithium battery sector performed well, with stocks like Jin Yuan Co. and Guoji General hitting their daily limits [6] - A recent announcement from Cangge Mining regarding the suspension of its lithium resource operations due to violations has raised concerns about compliance in the mining sector [6] - The adjustment of the "China Prohibited Export Technology Directory" includes new regulations on battery materials, which may affect the competitive landscape for domestic companies [8] Pharmaceutical Sector - The pharmaceutical sector continued to be active, with Han Shang Group and Renmin Tongtai achieving consecutive gains, and Angli Kang hitting the daily limit [9][10] - The Hong Kong Stock Connect Innovative Drug Index has seen a cumulative increase of 108.21% over the past year, indicating strong market confidence in the innovative drug sector [9] - Domestic innovative drugs are expected to see increased sales supported by medical insurance negotiations and commercial insurance [10]